ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: Trinity Biotech Plc Sponsored ADR Class A (TRIB) Report Updated: Oct 19, 2014 | Print This Page

Get more stock ratings by Louis Navellier

Trinity Biotech Plc Sponsored ADR Class A (TRIB)

Rating: Sell Volatility: Conservative
Total Grade: D Industry: Health Care Equipment & Supplies
Competitors: CFN, NVCN, ZLTQ, VASC
service keys

Trinity Biotech Plc Sponsored ADR Class A© quotemedia

Company Profile

Trinity Biotech plc acquires, develops, manufactures, distributes, and sells diagnostic test kits and instrumentation for the clinical laboratory and point-of-care segments of the diagnostic market. It offers clinical laboratory products, including diagnostic tests and instrumentation, which detect autoimmune, infectious, and sexually transmitted diseases; diabetes and hemoglobin disorders; and disorders of the liver and intestine. The company also provides UniGold HIV, a point of care diagnostic test, which are carried out in the presence of the patient to diagnose the presence of HIV antibodies in the patient. In addition, it sells raw materials to the life sciences industry and research institutes. Further, the company offers in-vitro diagnostic tests for haemoglobin A1c (HbA1c) used in the monitoring and diagnosis of diabetes; and Hb Variants for the detection of Hemoglobinapothies. Its customers include hospitals, clinical and reference laboratories, public health facilities, and other outreach facilities. The company sells its products directly in the United States, Germany, France, and the United Kingdom; and through a network of independent distributors and strategic partners in approximately 75 countries worldwide. Trinity Biotech plc was founded in 1992 and is headquartered in Bray, Ireland.

Recent News: Trinity Biotech Plc Sponsored ADR Class A